US Edition
Published • loading... • Updated
/C O R R E C T I O N -- Diakonos Oncology/
The presentations include updated pancreatic cancer findings and the first glioblastoma results from an expanded-access program, the company said.
- Diakonos Oncology Corp. will present new clinical trial data for its DOC1021 therapy at the American Association for Cancer Research Annual Meeting April 17-22 in San Diego and the American Academy of Neurology Annual Meeting April 18-22 in Chicago.
- DOC1021 is a first-in-class, patient-derived double-loaded dendritic cell investigational therapy combining tumor lysate and amplified tumor-derived mRNA without requiring genetic engineering or preconditioning chemotherapy. Statement 78, 83.
- Diakonos currently enrolls patients in a Phase 1 pancreatic cancer study and a Phase 2 glioblastoma study, with both programs receiving FDA Fast Track designation in October 2023 and May 2024, respectively. Statement 76, 27.
- "Presenting data at both of these conferences confirms the potential impact of DOC1021 across some of the most challenging cancers," President and COO Jay Hartenbach of Diakonos Oncology said. Statement 81.
- Early this year, Diakonos will initiate a Phase 1/2 refractory melanoma study with facilitation and support from the Cancer Prevention and Research Institute of Texas . Statement 73.
Insights by Ground AI
23 Articles
23 Articles
The Union Democrat+4 Reposted by 4 other sources
/C O R R E C T I O N -- U.S. Gold Corp./
In the news release, U.S. GOLD CORP. DELIVERS ROBUST FEASIBILITY STUDY FOR CK GOLD PROJECT HIGHLIGHTING ATTRACTIVE ECONOMICS AND DETAILING RELATIVE LOW DEVELOPMENT RISK, issued 31-Mar-2026 by U.S. Gold Corp. over PR Newswire, we are advised by the company of…
WJFW NewsWatch 12+17 Reposted by 17 other sources
/C O R R E C T I O N -- Diakonos Oncology/
In the news release, Diakonos Oncology to Showcase DOC1021 (dubodencel) Clinical Data in Pancreatic Cancer and Glioblastoma at AACR and ANN 2026, issued 18-Mar-2026 by Diakonos Oncology over PR Newswire, we are advised by the company that the headline should…
Coverage Details
Total News Sources23
Leaning Left0Leaning Right1Center14Last UpdatedBias Distribution93% Center
Bias Distribution
- 93% of the sources are Center
93% Center
C 93%
Factuality
To view factuality data please Upgrade to Premium
